Majority of Patients with Colorectal, Lung Cancer Believe Surgery Is Cure
the Cancer Therapy Advisor take:
Participants in this study included 3,954 patients who underwent surgery for lung (30.3%) or colorectal (69.7%) cancer between 2003 and 2005. These patients were identified from a population- and health system-based survey from across the United States.
Approximately 80.0% of patients with lung cancer and 89.7% with colorectal cancer reported that they believed surgical resection would cure their cancer.
Of patients with stage IV lung cancer, 57.4% also believed surgery would cure their disease, along with 79.8% of patients with stage IV colorectal cancer.
The belief of curative surgery was found to be higher among patients with colorectal cancer versus those with lung cancer (OR = 2.27).
Results showed that single, female patients with an advanced tumor stage and having a high number of comorbidities were less likely to have the belief that surgery would cure their cancer. Patients who communicated effectively with their physician and shared a role in decision-making with their physician (OR = 1.16) or family (OR = 1.17) had a higher perception that surgery would be a cure.
However, patients who did not have hands-on participation in decision-making and reported a physician-controlled (OR = 0.56) or family-controlled (OR = 0.72) approach were less likely to believe surgery would be curative.
The study suggests improvement be made in the patient-physician engagement and communication mechanism. Additionally, the authors recommend that barriers regarding the discussion of goals of care with patients diagnosed with cancer be addressed.
A majority of patients with lung and colorectal cancer reported perceptions that surgery would cure their cancer.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Pembrolizumab Prolongs Overall Survival Compared With Ipilimumab in Melanoma
- Atezolizumab Monotherapy Effective in PD-L1 Non-small Cell Lung Cancer
- Checkpoint Inhibition in Multiple Myeloma After Pembrolizumab-related Clinical Trial Deaths
- NSCLC: Genetic Mutations May Determine Likelihood of Metastasis at Diagnosis
- Pembrolizumab Demonstrates Safety and Efficacy in Small-cell Lung Cancer